NEW YORK (GenomeWeb) – Microbial genetics analysis firm OpGen plans to offer 3.75 million shares of its common stock for its planned initial public offering, the company said in an amended Form S-1 today. 

The company said that it plans to offer its stock at a price between $8 and $10 per share. At the midpoint price of $9, OpGen anticipates the IPO will bring in net proceeds of about $30.5 million, or $35.2 million if the offering's underwriter exercises its overallotment option in full. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.